Clinical trial

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.

NCT05867212

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2023-05-13

PhaseN/A

Study timeline

Study start (actual)2023-05-13Date precision: day

Registry last updated2025-07-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV Infectionsunresolved

Interventions

Cabotegravir Injection [Apretude]DRUG · verified · RxNorm: cabotegravir Injection [Apretude]

Sponsors & collaborators

Kelley-Ross & Associates, Inc.lead sponsor

Mapped research locations

SeattleWashington, United States2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05867212 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.